The pan-Canadian Advisory Panel on a Framework for a Prescription Drug List


( Last Updated : October 21, 2021)

Overview

In Canada, coverage for prescription drugs exists through an array of public and private drug plans.

The pan-Canadian Advisory Panel on a Framework for a Prescription Drug List (Advisory Panel) is creating a recommended framework for developing a potential pan-Canadian prescription drug list, or formulary.

The Advisory Panel’s non-binding recommendations are intended to add to the national conversation about ensuring Canadians have access to prescription drugs.

The mandate of the Advisory Panel is to:

  • recommend principles and a framework for developing a pan-Canadian prescription drug list
  • recommend an initial list of commonly prescribed drugs and a transparent way to add to that list
  • consult with key stakeholders and health system partners, including federal, provincial, and territorial governments; patients; clinicians; industry; and others.

The Advisory Panel’s non-binding recommendations will be completed by the end of April 2022. The Advisory Panel’s final report will be submitted to Health Canada, shared with provincial and territorial governments, and made available publicly.

CADTH is providing oversight and facilitating the work of the Advisory Panel.

Project Timeline

project timeline

Pan-Canadian Advisory Panel Members

The Advisory Panel is composed of 2 co-chairs and 12 members. Its members were recruited from across Canada and represent diversity across gender, culture, and race. The Advisory Panel brings together a range of expertise and experience, including health care providers (nursing, pharmacy, and medicine), persons with lived and living experience, and individuals with backgrounds in ethics and health policy.

Panel Members of the Pan-Canadian Advisory Panel on a Framework for a Prescription Drug List

 

Name

Province

Bios

Co-Chairs

Alexandra King

Alexandra

BSc, BBA, MD, FRCPC

Saskatchewan

Dr. Alexandra King is an internal medicine specialist with a focus on HIV/AIDS, hepatitis C, and HIV and oft-related conditions. Alexandra is a member of the Nipissing First Nation (Ontario) and the Cameco Chair in Indigenous Health and Wellness at the University of Saskatchewan.

Conflict of Interest Disclosure

Allen Lefebvre 

Allen

Saskatchewan

Allen Lefebvre has served in several management and volunteer leadership capacities primarily in the charitable and not-for-profit sectors. Allen is a long-standing public member on the CADTH Canadian Drug Expert Committee and has been a public representative on the Drug Advisory Committee of Saskatchewan since 2010.

Conflict of Interest Disclosure

Members 

Stéphane Ahern

Stephane

MA, MD, FRCPC, PhD

Quebec

Dr. Stéphane P. Ahern is an adult intensive care and general internal medicine specialist at CIUSSS de l’Est-de-l’Île-de-Montréal – Hôpital Maisonneuve-Rosemont and an Associate Professor in the Faculty of Medicine at the University of Montreal. He holds a master’s degree in philosophy, with a focus on clinical ethics, and a PhD in clinical science. For many years, he has been interested in the evaluation of drug reimbursements for the Institut national d’excellence en santé et en services sociaux Standing Scientific Committee on Entry on the List of Medications.

Conflict of Interest Disclosure

Shawn Bugden

shawn

BSc (Hons), BSc (Pharm), MSc, PharmD

Newfoundland and Labrador

Dr. Shawn Bugden is Dean at the School of Pharmacy at Memorial University of Newfoundland and Labrador and an Adjunct Professor at the College of Pharmacy at the University of Manitoba. Shawn is also on the Board of Directors for the Canadian Pharmacists Association. Shawn has expertise in hospital pharmacy, health policy, pharmacoepidemiology, pharmacovigilance, and pharmacoeconomic evaluation.

Conflict of Interest Disclosure

Connie Côté

connie

MA

Ontario 

Connie Côté is the Chief Executive Officer of the Health Charities Coalition of Canada. Connie has extensive experience in the not-for-profit health sector. Connie’s area of interests include health policy, health research, and promoting the voices of patients and caregivers. Connie is a current care provider.

Conflict of Interest Disclosure 

Elsie Duff 

elsi

BScN, RN, NP, MEd, PhD 

Manitoba

Dr. Elsie Duff is a nurse practitioner and an assistant professor in the College of Nursing, Rady Faculty of Health Sciences, University of Manitoba. Elsie has lived and worked in rural and remote locations in Manitoba and has extensive expertise as a first-line provider of primary health care and virtual care, episodic care, disease prevention, and promotion of health. Elsie has served on several university and community boards and committees. 

Conflict of Interest Disclosure

Bashir Jiwani

Bashir

MA, PhD

British Columbia

Dr. Bashir Jiwani is Executive Director, Ethics and Diversity Services, at the Fraser Health Authority. Recent areas of focus include allocating financial resources to support COVID-19 response, producing decision-making structures and processes for expensive drugs for rare diseases, and creating a gender-inclusive climate. Bashir currently serves on the Drug Benefit Council for BC Ministry of Health; the Expensive Drugs for Rare Diseases Committee for BC Ministry of Health; the Core Team for the Aga Khan University Thinking Group on Ethics, Stem Cell Science, and Regenerative Medicine; and as a consultant for the Ismaili Tariqah and Religious Education Board of Canada. Bashir is President-Elect of the Canadian Bioethics Society. 

Conflict of Interest Disclosure 

Diane McArthur 

Diana

BPR, MBA

Ontario

Diane McArthur is a former Ontario public servant. Diane was Ontario’s first Chief Talent Officer and Associate Deputy Minister with the Centre for Leadership and Learning in the Treasury Board. Diane was also the Assistant Deputy Minister and Executive Officer, Ontario Public Drug Programs Division. Diane is currently an active member on several boards in the broader public sector sharing her experience in government relations, governance, and program administration. 

Conflict of Interest Disclosure

Andrew Pinto

Andrew 

MSc, MD, CCFP, FRCPC  

Ontario

Dr. Andrew Pinto is the founder and director of the Upstream Lab, a research team focused on integrating health and social care, population health management, and data to enable proactive care. Andrew is a Public Health and Preventive Medicine specialist and family physician at St. Michael’s Hospital, and a scientist at MAP at the Li Ka Shing Knowledge Institute, Unity Health Toronto. Andrew is an Associate Professor at the University of Toronto, appointed to the Department of Family and Community Medicine, the Institute for Health Policy, Management and Evaluation, and the Dalla Lana School of Public Health. 

Conflict of Interest Disclosure 

Sheri Roach 

Sheri

RN, MN, MHA 

Nova Scotia 

Sheri Roach is a registered nurse with a background in direct care, health care leadership, policy, and education. Sheri is a faculty member at Dalhousie University’s School of Nursing and sits on the Board of Directors for the Canadian Nurses Association. 

 

Conflict of Interest Disclosure 

Adil Virani 

Adil

BSc (Pharm), PharmD 

British Columbia 

Dr.Adil Virani is a manager with Lower Mainland Pharmacy Services and has hospital, community, and university experience in British Columbia and Nova Scotia. Adil has been a member of the CADTH Canadian Drug Expert Committee and the Patented Medicine Prices Review Board’s Human Drug Advisory Panel since 2008. 

 

Conflict of Interest Disclosure 

Cornelia (Nel) Wieman 

Nel

MSc, MD, FRCPC 

British Columbia 

Dr. Cornelia (Nel) Wieman is Canada’s first female Indigenous psychiatrist. Nel is President of the Indigenous Physicians Association of Canada and Acting Deputy Chief Medical Officer in the Office of the Chief Medical Officer at the First Nations Health Authority in British Columbia. 

Conflict of Interest Disclosure 

Sam Wong 

Sam

MD, FRCPC 

Alberta and the Northwest Territories  

Dr. Sam Wong is a pediatrician who works part-time in Yellowknife in general pediatrics and travel clinics for a variety of communities in the Northwest Territories and Nunavut. Sam is also a part-time hospital pediatrician at the Stollery Children’s Hospital in Edmonton. Most recently, Sam was the chair of the First Nations, Inuit, and Métis Health Committee of the Canadian Pediatric Society. Sam is currently president of the Canadian Pediatric Society (2020–2021). 

 

Conflict of Interest Disclosure 

Yan Yu 

Yan

MD, MPP, MBA, CCFP 

Alberta 

Dr. Yan Yu is a family physician in Alberta and the Northwest Territories and is a member of the College of Family Physicians of Canada Board of Directors. Yan practices in numerous clinical settings, such as community-based family medicine clinics, long-term care homes, hospitals, and rural emergency rooms. Yan’s clinical interests include working in emergency psychiatry and providing care to rural, remote, and Indigenous communities. 

 

Conflict of Interest Disclosure 

FAQs

1. Who is on the Advisory Panel?

The names, biographies, and conflict of interest declarations of the 14 Advisory Panel members are outlined in the table of panel members.

The Advisory Panel is composed of 14 members:

  • 2 co-chairs (a physician and a patient member)
  • 1 ethicist
  • 1 former Assistant Deputy Minister–level drug plan lead
  • 1 nurse practitioner and 1 registered nurse
  • 1 representative of a national health charity
  • 2 pharmacists
  • 5 physicians (generalists and specialists).
     

2. How were the Advisory Panel members chosen?

CADTH selected the Advisory Panel members with advice and guidance from its federal, provincial, and territorial funders.

The Advisory Panel is composed of 2 co-chairs and 12 members who represent diversity across gender, culture, race, and geography. Its membership brings together a range of expertise and experience, including health care providers (nursing, pharmacy, and medicine), persons with lived and living experience, and individuals with backgrounds in ethics and health policy.
 

3. What is the Advisory Panel’s scope of work?

The Advisory Panel is time limited. Its scope includes:

  • recommend principles and a framework for developing a pan-Canadian prescription drug list
  • recommend an initial list of commonly prescribed drugs and a transparent way to add to that list
  • consult with key stakeholders and health system partners, including federal, provincial, and territorial governments; patients; clinicians; industry; and others.
     

4. What will happen with the Advisory Panel’s recommendations?

The Advisory Panel’s recommendations will contribute to discussions about a potential pan-Canadian prescription drug list. Progress reports will be produced and made public throughout the initiative. The Advisory Panel recommendations will be completed by the end of April 2022, and a report will be submitted to Health Canada, shared with provincial and territorial governments, and made publicly available.
 

5. What is CADTH’s involvement in this initiative?

CADTH is providing oversight and facilitating the work of the Advisory Panel.
 

6. How can I get involved?

On behalf of the Advisory Panel, CADTH will be reaching out to stakeholders to solicit input and feedback during this initiative.

The Advisory Panel will be hosting a 3-part webinar series to allow stakeholders to provide feedback on its proposed recommendations. The webinars will be held between late October and early December 2021. These will be promoted through CADTH’s regular communications channels. Stakeholders will also have an opportunity to provide written submissions.

To receive updates on engagement opportunities, please subscribe to CADTH e-Alerts.
 

Contact

If you have questions about the pan-Canadian Advisory Panel on a Framework for a Prescription Drug List or its work, please email them to CADTH.